Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaVitamin A Transport Mechanism of the Multitransmembrane Cell-Surface Receptor STRA6Inorganic Arsenic-induced cellular transformation is coupled with genome wide changes in chromatin structure, transcriptome and splicing patternsArsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesPML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA associationL-type calcium current (ICa,L) and inward rectifier potassium current (IK1) are involved in QT prolongation induced by arsenic trioxide in rat.MYB suppresses differentiation and apoptosis of human breast cancer cells.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsA serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.Ganoderma lucidum Polysaccharides Induce Macrophage-Like Differentiation in Human Leukemia THP-1 Cells via Caspase and p53 Activation.New perspectives on chinese herbal medicine (zhong-yao) research and developmentRecent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.Interferon-γ enhances promyelocytic leukemia protein expression in acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of NB4 and NB4-R1 cells.Trisomy 11 as an additional chromosome alteration in a child with acute promyelocytic leukemia with poor prognosis.Pseudotumor cerebri presenting with visual failure in promyelocytic leukemia: a case report.Advances in paediatric cancer treatmentTargeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.Differential and isomer-specific modulation of vitamin A transport and the catalytic activities of the RBP receptor by retinoidsAquaglyceroporins and metalloid transport: implications in human diseases.Aquaglyceroporins: generalized metalloid channels.Bioengineering approaches to study multidrug resistance in tumor cells.Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles.Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistance.PML-RARA mutations confer varying arsenic trioxide resistance.Introduction. China in the era of life science and biotechnology.Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.TRIM proteins in blood cancers.Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel.Arsenic trioxide and olanzapine co-administration: case analysis.Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells
P2860
Q24605527-EDEB9B17-69BF-4FD3-BC72-6E40F167533DQ26783584-368510F3-BD3E-4172-A130-65032F8A44A0Q28390396-993DE0A0-A40E-4D2F-8985-C8997CB739BCQ33551142-B2B5F2C9-7853-4D33-90DE-074B3977B487Q33730375-B42FACDE-2FC2-4C45-8311-E392CEDC6232Q33734488-2893430A-BD6E-4295-B670-B56FD3F8D3F0Q33789857-93996478-0136-4B87-A1A9-232351AB0BBFQ34173485-1C1371F6-30E7-4913-8264-E1C085BAF77AQ34218232-C0C99312-B1C3-41AA-B4E7-E026F5C07B3AQ34305899-BA56E98D-CCF9-40CD-8098-3243FD41B0D9Q34701049-9DDA6C3B-C41E-4ECE-8E56-4EE3B37D7E2CQ35102187-BE5FB4E0-B359-4303-9E31-E60735A376E3Q35102748-47B4BF52-5076-42E9-B0E1-6B21C8B7155DQ35459525-4319220D-4A32-40B7-964C-E9BEFCB20637Q36224305-D228EF88-D18C-440B-ADEE-0075123958ABQ36248003-0D2F4FAA-A221-4ABB-BA8F-C950561C91E6Q36462605-D029B863-0688-4642-B0B6-1C3E31262A2AQ36508630-9D16C160-A653-4C2F-ACCF-624C7ABDACE1Q37144023-716643C6-9A22-48AF-8CAA-04E52BB08569Q37184481-9D1D241B-4773-4E1E-9D17-9F5BEEC063BEQ37310939-8FAFB3FF-6E20-4A5C-84AA-53E7D5D20C5AQ37649779-F8DD2815-E088-4F30-862B-3586EBE4AF63Q37851027-F6067BE1-3ED7-4B5C-8EB8-177B57070F13Q37890950-50BF31CE-7C33-40E8-9472-AFCD092DBF70Q38020145-CF48B36B-73E0-4EB1-8FD5-8F26C0490879Q38185419-C0FC8475-7CFE-4287-B289-49645DB35731Q38221006-2494C049-37ED-41D2-8621-B335715BE69AQ38798789-1E6781B7-E20D-4DC0-899D-0CCDF41AB1C4Q39147156-FF945E15-5792-4042-A812-51EE2647F975Q39445570-CD71A589-A39D-4B21-A37C-D5622395FD8FQ39852728-B7374219-4F52-453A-A96A-26B45DC2E8B5Q42315118-1622A806-EAD4-41A3-8C21-204C7D7ECF4AQ45918164-FA9459F2-0E2B-4B51-ADAA-1E484C995C5CQ46246849-646525D9-336C-46B9-8176-E653A11D181BQ47433060-BFA14138-8132-494A-8A8D-CCB65773984BQ48791883-C41F9B4D-AD50-4A47-9D6D-19838D385EF7Q51859079-A089B09C-D69A-4E8B-9E32-561BE0DD8177Q58764406-BABD117E-4A3E-4057-81C9-75C0B214DE56
P2860
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Treatment of acute promyelocyt ...... c molecular targeting therapy.
@ast
Treatment of acute promyelocyt ...... c molecular targeting therapy.
@en
type
label
Treatment of acute promyelocyt ...... c molecular targeting therapy.
@ast
Treatment of acute promyelocyt ...... c molecular targeting therapy.
@en
prefLabel
Treatment of acute promyelocyt ...... c molecular targeting therapy.
@ast
Treatment of acute promyelocyt ...... c molecular targeting therapy.
@en
P2093
P2860
P356
P1476
Treatment of acute promyelocyt ...... ic molecular targeting therapy
@en
P2093
Sai-Juan Chen
Zhen-Yi Wang
P2860
P304
P356
10.1098/RSTB.2007.2026
P407
P577
2007-06-01T00:00:00Z